Allergan Stock Price, Forecast & Analysis (NYSE:AGN)

Allergan trades on the New York Stock Exchange (NYSE) under the ticker symbol "AGN."

Allergan declared a quarterly dividend on Friday, October 25th. Shareholders of record on Wednesday, November 13th will be given a dividend of $0.74 per share on Friday, December 13th. This represents a $2.96 annualized dividend and a yield of 1.63%. The ex-dividend date is Tuesday, November 12th. View Allergan's Dividend History.

Allergan announced that its board has authorized a stock repurchase program on Tuesday, January 29th 2019, which allows the company to repurchase $2,000,000,000.00 in shares, according to EventVestor. This repurchase authorization allows the company to repurchase up to 4.1% of its shares through open market purchases. Shares repurchase programs are usually an indication that the company's board of directors believes its stock is undervalued.

Allergan plc (NYSE:AGN) announced its quarterly earnings results on Tuesday, November, 5th. The company reported $4.25 EPS for the quarter, meeting the Zacks' consensus estimate of $4.25. The company had revenue of $4.03 billion for the quarter, compared to analysts' expectations of $3.88 billion. Allergan had a positive return on equity of 9.08% and a negative net margin of 58.50%. The business's revenue for the quarter was up 2.9% on a year-over-year basis. During the same period in the prior year, the business earned $4.25 EPS. View Allergan's Earnings History.

Allergan is scheduled to release their next quarterly earnings announcement on Tuesday, February 4th 2020. View Earnings Estimates for Allergan.

Allergan updated its FY19 earnings guidance on Tuesday, November, 5th. The company provided earnings per share (EPS) guidance of >$16.55 for the period, compared to the Thomson Reuters consensus estimate of $16.74. The company issued revenue guidance of $15.6-15.8 billion, compared to the consensus revenue estimate of $15.58 billion.

20 brokers have issued 12-month price targets for Allergan's stock. Their forecasts range from $144.95 to $200.00. On average, they expect Allergan's share price to reach $175.16 in the next twelve months. This suggests that the stock has a possible downside of 3.5%. View Analyst Price Targets for Allergan.

20 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Allergan in the last year. There are currently 15 hold ratings and 5 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Allergan.

News stories about AGN stock have been trending very negative on Monday, according to InfoTrie Sentiment. InfoTrie rates the sentiment of press coverage by analyzing more than six thousand blog and news sources. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores closest to five being the most favorable. Allergan earned a media sentiment score of -3.2 on InfoTrie's scale. They also gave media headlines about the company a news buzz of 10.0 out of 10, meaning that recent press coverage is extremely likely to have an effect on the company's share price in the next several days. View News Stories for Allergan.

Allergan saw a increase in short interest in October. As of October 31st, there was short interest totalling 11,450,000 shares, an increase of 10.8% from the September 30th total of 10,330,000 shares. Based on an average daily trading volume, of 3,220,000 shares, the days-to-cover ratio is presently 3.6 days. Approximately 3.5% of the company's stock are sold short. View Allergan's Current Options Chain.

Some companies that are related to Allergan include Johnson & Johnson (JNJ), Merck & Co., Inc. (MRK), Pfizer (PFE), AbbVie (ABBV), Eli Lilly And Co (LLY), Bristol-Myers Squibb (BMY), Zoetis (ZTS), Mylan (MYL), Perrigo (PRGO), Jazz Pharmaceuticals (JAZZ), Horizon Therapeutics (HZNP), The Medicines (MDCO), Nektar Therapeutics (NKTR), Zogenix (ZGNX) and Pacira Biosciences (PCRX).

Based on aggregate information from My MarketBeat watchlists, some companies that other Allergan investors own include CA (CA), Endologix (ELGX), BlackRock (BLK), Chipotle Mexican Grill (CMG), Athabasca Oil (ATH), Micron Technology (MU), Aegean Marine Petroleum Network (ANW), NIC (EGOV), United Rentals (URI) and Transocean (RIG).

Allergan's stock is owned by a variety of of institutional and retail investors. Top institutional investors include Assenagon Asset Management S.A. (0.54%), Newport Trust Co (0.38%), California Public Employees Retirement System (0.24%), Diamond Hill Capital Management Inc. (0.20%), Strs Ohio (0.20%) and Rhumbline Advisers (0.15%). Company insiders that own Allergan stock include Brent L Saunders, Chris W Bodine, Christopher J Coughlin, Joseph H Boccuzi, Maria Teresa Hilado, Matthew M Walsh and William Meury. View Institutional Ownership Trends for Allergan.

AGN stock was sold by a variety of institutional investors in the last quarter, including Diamond Hill Capital Management Inc., State of New Jersey Common Pension Fund D, Robeco Institutional Asset Management B.V., Metropolis Capital Ltd, Russell Investments Group Ltd., Great West Life Assurance Co. Can, Envestnet Asset Management Inc. and Janney Capital Management LLC. View Insider Buying and Selling for Allergan.

AGN stock was bought by a variety of institutional investors in the last quarter, including Assenagon Asset Management S.A., Tibra Equities Europe Ltd, California Public Employees Retirement System, Zweig DiMenna Associates LLC, GABELLI & Co INVESTMENT ADVISERS INC., FNY Investment Advisers LLC, ARP Americas LP and Gabelli Funds LLC. Company insiders that have bought Allergan stock in the last two years include Brent L Saunders, Chris W Bodine, Christopher J Coughlin, Joseph H Boccuzi, Maria Teresa Hilado and Matthew M Walsh. View Insider Buying and Selling for Allergan.

Shares of AGN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of AGN stock can currently be purchased for approximately $181.58.

Allergan has a market capitalization of $59.61 billion and generates $15.79 billion in revenue each year. The company earns $-5,096,400,000.00 in net income (profit) each year or $16.69 on an earnings per share basis. Allergan employs 16,900 workers across the globe.View Additional Information About Allergan.

The official website for Allergan is http://www.allergan.com/.

Allergan's mailing address is CLONSHAUGH BUSINESS AND TECHNOLOGY PARK COOLOCK, DUBLIN L2, D17 E400. The company can be reached via phone at 862-261-7000 or via email at [email protected]